VNDA - バンダ・ファ―マシュ―ティカルズ (Vanda Pharmaceuticals Inc.) バンダ・ファ―マシュ―ティカルズ

 VNDAのチャート


 VNDAの企業情報

symbol VNDA
会社名 Vanda Pharmaceuticals Inc (バンダ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バンダ・ファーマシューティカルズ(Vanda Pharmaceuticals Inc.)は生物医薬品会社である。同社は、満たされていない医療ニーズに対応する治療法の開発・商品化を行う。同社の製品ポートフォリオには、HETLIOZ(tasimelteon)、Fanapt(iloperidone)、Tradipitant(VLY-686)、Trichostatin AおよびAQW051がある。同社は非24時間睡眠覚醒障害(24歳未満)の治療にHETLIOZを提供する。HETLIOZは、Pediatric Non-24、Jet Lag DisorderおよびSmith-Magenis症候群の治療用の臨床開発中である。同社は統合失調症の治療用のFanaptを提供する。Fanaptは、多様な他の障害において有用性がある。Tradipitantは、小分子ニューロキニン-1受容体(NK-1R)アンタゴニストであり、アトピー性皮膚炎における慢性掻痒の治療のための臨床開発中である。トリコスタチンAは、小分子ヒストンデアセチラーゼ(HDAC)阻害剤である。AQW051は、第II相アルファ-7ニコチン性アセチルコリン受容体部分アゴニストである。AQW051は、中枢神経系障害の治療に適応する。   バンダ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。中枢神経系障害の治療用の薬品を開発、商業化する。主要な製品には、24時間睡眠覚醒障害の治療用に「HETLIOZ」、統合失調症の治療用に「Fanapt」、アトピ―性皮膚炎の治療用に小分子ニュ―ロキニン-1受容体拮抗薬「VLY-686」などがある。   Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
本社所在地 2200 Pennsylvania Avenue N.W. Suite 300 E Washington DC 20037 USA
代表者氏名 H. Thomas Watkins H.トーマス・ワトキンス
代表者役職名 Independent Chairman of the Board
電話番号 +1 202-734-3400
設立年月日 37561
市場名 NASDAQ National Market System
ipoyear 2006年
従業員数 273人
url www.vandapharma.com
nasdaq_url https://www.nasdaq.com/symbol/vnda
adr_tso
EBITDA EBITDA(百万ドル) 2.28300
終値(lastsale) 23
時価総額(marketcap) 1204727235
時価総額 時価総額(百万ドル) 1123.539
売上高 売上高(百万ドル) 176.55400
企業価値(EV) 企業価値(EV)(百万ドル) 892.32300
当期純利益 当期純利益(百万ドル) 1.28900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Vanda Pharmaceuticals Inc. revenues increased 14% to $90.9M. Net income totaled $7.7M vs. loss of $9.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Selling General and administrative - decrease of 14% to $49.5M (expense) Other income increase from $677K to $1.4M (income).

 VNDAのテクニカル分析


 VNDAのニュース

   This company gets FDA green light to proceed with study on possible COVID-19 treatment  2020/04/21 21:14:05 Yahoo Finance
Vanda Pharmaceuticals CEO Dr. Mihael Polymeropoulos joins Yahoo Finance's Seana Smith on what's next for the company's potential coronavirus treatment drug after receiving approval from the FDA for a clinical trial.
   Vanda Begins Enrollment in Study for Severe Coronavirus Infection  2020/04/16 14:58:00 Zacks Investment Research
Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.
   The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More  2020/03/03 12:51:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Vanda -4.1% amid profit miss, EPIONE study  2020/02/25 23:36:24 Seeking Alpha
Vanda Pharmaceuticals (NASDAQ:VNDA) is 4.1% lower after hours, following a miss on Q4 profits alongside news that its Phase III EPIONE clinical trial did n
   The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More  2020/03/03 12:51:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Vanda -4.1% amid profit miss, EPIONE study  2020/02/25 23:36:24 Seeking Alpha
Vanda Pharmaceuticals (NASDAQ:VNDA) is 4.1% lower after hours, following a miss on Q4 profits alongside news that its Phase III EPIONE clinical trial did n
   Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis  2020/02/25 21:13:00 PR Newswire
WASHINGTON, Feb. 25, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:VNDA) today announced results from a Phase III clinical trial (EPIONE) of tradipitant for the treatment of pruritus in atopic dermatitis (AD) in adults. The EPIONE study did not meet its primary endpoint…
   Vanda Pharmaceuticals EPS misses by $0.03, beats on revenue  2020/02/25 21:08:31 Seeking Alpha
Vanda Pharmaceuticals (NASDAQ:VNDA): Q4 GAAP EPS of $0.08 misses by $0.03. Revenue of $60.9M (+14.8% Y/Y) beats by $1.32M. Shares +0.4%. Press Release
   The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More  2020/03/03 12:51:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Vanda -4.1% amid profit miss, EPIONE study  2020/02/25 23:36:24 Seeking Alpha
Vanda Pharmaceuticals (NASDAQ:VNDA) is 4.1% lower after hours, following a miss on Q4 profits alongside news that its Phase III EPIONE clinical trial did n
   Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis  2020/02/25 21:13:00 PR Newswire
WASHINGTON, Feb. 25, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:VNDA) today announced results from a Phase III clinical trial (EPIONE) of tradipitant for the treatment of pruritus in atopic dermatitis (AD) in adults. The EPIONE study did not meet its primary endpoint…
   Vanda Pharmaceuticals EPS misses by $0.03, beats on revenue  2020/02/25 21:08:31 Seeking Alpha
Vanda Pharmaceuticals (NASDAQ:VNDA): Q4 GAAP EPS of $0.08 misses by $0.03. Revenue of $60.9M (+14.8% Y/Y) beats by $1.32M. Shares +0.4%. Press Release

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バンダ・ファ―マシュ―ティカルズ VNDA Vanda Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)